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Summary Persistence of high levels of radiolabelled antibody in the circulation is a major limitation of
radoioumunotherapy. Biotinylation of the radiolabelled anti-tumour antibody followed by administration of
streptavidin is known to give much improved tumour to blood ratios as the radioantibody is complexed and
subsequently cleared via the reticuloendothelial system, although prolonged splenic uptake is a problem. We
have investigated the effect on the clearance pattern and tumour localisation of a '2I-labelled biotinylated
anti-CEA antibody (A5B7) after administration of a galactosylated form of streptavidin (gal-streptavidin) in
nude mice bearing a human colon carcinoma xenograft. Fifteen minutes to I h after gal-streptavidin admini-
stration the complexes were cleared via the liver alone (as opposed to liver and spleen after native strep-
tavidin) Twenty-four hours after administration of gal-streptavidin, the tumour to blood ratio for biotinylated
A5B7 IgG increased from 2.9 to 13.2 and for biotinylated F(ab')2 fragments an increase from 4.9 to 33.2 was
achieved. The reduction in tumour accumulation of F(ab'), 24 h after injection of the clearing agent was less
than that seen with intact antibody. Injection of asialofetuin inhibited clearance. confirming that removal of
the gal-streptavidin-biotinylated antibody complexes from the blood was via the asialoglycoprotein receptor
on liver hepatocytes. Therefore, galactosylation of the streptavidin clearing agent allows rapid removal of
radiolabelled biotinylated antibodies via the liver asialoglycoprotein receptor. as opposed to the reticuloendo-
thelial system.
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Effective radioimmunotherapy is dependent upon achieving
high doses of radiolabelled antibody at the tumour site, but
the persistence of antibody in the circulation results in low
tumour to blood ratios. The therapeutic dose is therefore
limited by the potential damage to bone marrow and other
normal tissues caused by circulative radioactive antibody. To
improve tumour to blood ratios, and hence increase the dose
of radioactivity which can be safely given, a method of
controlling the removal of the circulating radioactive
antibody is required.
Benacerraf et al. in 1959 reported that antibody complexes
are rapidly cleared from the circulation via the reticuloen-
dothelial system (RES): the larger the complex, the faster the
clearance. Various groups have used second antibodies reac-
tive against the first anti-tumour antibodies to form large
immune complexes and thus clear damaging circulating
radioactive antibodies via the RES, resulting in a much
improved therapeutic ratio (Begent et al., 1982; Sharkey et
al., 1984; Pedley et al., 1989).
More recent work has shown that forming antibody com-
plexes of biotinylated antibodies using avidin or streptavidin
also results in rapid clearance of antibodies from the circula-
tion in animals (Sinitsyn et al., 1989) and in man (Paganelli
et al., 1990a), and this clearing method gives much improved
therapeutic ratios needed for radioimmunotargeting (Mar-
shall et al., 1994). This clearing strategy is of great interest as
it utilises the very high affinity of avidin (and streptavidin)
for biotin (Ka = I0" M-1) and biotinylation (via lysine
residues) should be applicable to any anti-tumour antibody,
including antibody fragments.
Although the above clearing strategies have given greatly
improved tumour to blood ratios, clearance via the RES
results in raised liver and splenic radioactivity, which
decreases rapidly from the liver but persists in the spleen
giving rise to the risk of splenic radiotoxicity.
Much work has focused on how the clearance of proteins
and immune complexes can be altered. The asialoglyco-
protein receptor on liver hepatocytes (Ashwell and Morell,
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1974) has also been implicated in the clearance of immune
complexes (Thornberg et al., 1980), and manipulation of the
carbohydrate content has been shown to direct the clearance
of proteins and immune complexes to the liver (Rogers and
Kornfeld, 1971; Rifai et al., 1982). Therefore, it seems likely
that galactosylation of streptavidin will preferentially direct
streptavidin-biotinylated antibody complexes to the
hepatocytes of the liver.
Therefore, we have investigated the use of a galactosylated
form of streptavidin as a clearing agent for '215-labelled
biotinylated A5B7, an anti-CEA murine monoclonal anti-
body, with a view to diverting clearance of damaging cir-
culating radioantibodies via asialoglycoprotein receptors on
hepatocytes of the liver in preference to macrophages, and so
circumventing prolonged exposure of the spleen to radiation.
We have investigated the effect of galactosylated streptavidin
administration on tumour localisation and biodistribution in
normal tissues of biotinylated intact A5B7 and biotinylated
F(ab)2 A5B7 injected into nude mice bearing the human
colon carcinoma xenograft LS174T. To illustrate the involve-
ment of the asialoglycoprotein receptor in the clearance
mechanism, the effect of fetuin and asialofetuin on the blood
and tissue uptake of the galactosylated complexes was also
examined. Asialofetuin, but not fetuin, is known to bind to
the asialoglycoprotein receptor of the liver and therefore
inhibits blood clearance of other proteins normally cleared
via this receptor.
MateriaL and metbod
Antibody preparation
F(ab')2 fragments A5B7, a monoclonal murine anti-CEA
antibody (Pedley et al., 1987), was concentrated (20mgml-
in 0.1 M sodium acetate, pH 4.5) and digested with Pepsin
(Sigma, Poole, UK) (4 mg per 75 mg of antibody) at 37°C for
48 h with gentle mixing. After dialysis against phosphate-
buffered saline (PBS), pH 7.4, the F(ab'), fragments were
purified by affinity chromatography on protein A (Phar-
macia, Uppsala, Sweden) followed by gel filtration on
Sephacryl S-200 (Pharmacia, Uppsala, Sweden). FractionsD - dasa -- *
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containing F(ab% were pooled and purity was checked by
SDS-PAGE.
Biotinylation ofintact and F(ab')2 fragments Caproylamido-
biotin-NHS ester (Sigma, Poole, UK) in dimethylsuphoxide
(DMSO) (5 mg ml-') was added to the antibody (1 mg ml'-
in 0.1 M sodium bicarbonate buffer, pH 8.5) at a 24: 1 molar
ratio for intact A5B7 and 30:1 molar ratio for F(ab% A5B7
and incubated at room temperature for 4 h with constant
gentle agitation. The antibody was then dialysed against PBS,
pH 7.4, at 4-C to remove any unreacted biotinylation re-
agents. This resulted in intact A5B7 with approximately ten
biotins per antibody molecule and F(ab% A5B7 with approx-
imately eight biotins per antibody molecule, as assessed using
a 4'-hydroxyazobenzene-2-carboxylic acid (HABA) dye assay
(Pierce and Warr, Chester, UK) (Green, 1965). CEA
binding after biotinylation was checked by enzyme-linked
immunosorbent assay (ELISA) on CEA-coated wells, and
also after radiolabelling by affinity chromatography on a
CEA-Sepharose column. CEA binding of radiolabelled bio-
tinylated intact and biotinylated F(ab%2 A5B7 was reduced
by approximately 3% and 13% respectively in comparison
with radiolabelled unmodified antibodies.
Radiolabelling Radiolabelling with "2I was carried out by
the lodo-gen method (Fraker and Speck, 1978) for 20min to
a specific activity of approximately 0.5 mCi 0.5 mg-' protein.
Chloramine T should not be used to radiolabel biotinylated
antibodies as this harsh oxidation method has a detrimental
effect on the biotin residues.
Galactosylation ofstreptavidin
Cyanomethyl-2,3,4,6-tetra-O-acetyl-I-thio-p-D-galactopyran-
oside (Sigma), (0.1 M in dry methanol) was mixed with 10% of
0.1 M sodium methoxide, also in dry methanol, and allowed
to stand for 48 h. A 0.8 ml aliquot of this solution was added
to a round-bottomed flask and evaporated to dryness, after
which 5 mg streptavidin (5 mgml-' in 25 mM sodium borate,
pH 8.5) was added and allowed to react for 2 h. The gaa-
tosylated streptavidin was then purified by gel filtration on
Sephadex G25 (Pharmacia, Uppsala, Sweden) and carbohyd-
rate content assayed by the phenol-sulphuric acid method of
Dubois et al. (1956) using a galactose standard. This showed
the streptavidin to contain 240 jg of galactose per mg. When
5.6 ml of the galactopyranoside solution was dried and
reacted with 37mg of strptavidin (lOmgml-' in 25mM
sodium borate, pH 8.5) then 71 jg galactose per mg of strep-
tavidin resulted.
In vivo studies
TO nude mice bearing the LS174T xenograft, established by
subcutaneous passagng of the human colon carcinoma cell
ie LS174T (Tom et al., 1976), were injected via the tail vein
with approximately IOMg IO Ci-I ['1Jfbiotinylated antibody.
Test animals were intraperitoneally injected with galac-
tosylated streptavidin at a 10-fold molar excess of the
antibody (Marshall et al., 1994) 24 h after injection of
biotinylated intact A5B7 or 9 h after injection of biotinylated
F(ab% A5B7. Test and control animals were bled and tissues
removed to be counted for radioactivity 15 mi, 1 h and 24 h
after gal-streptavidin for the intact A5B7 and 15 min, 1, 15
and 24 h after gal-streptavidin for the F(ab% A5B7.
The effect of fetuin and asialofetuin on the clearance of
galactosylated streptavidin complexes was assessed in TO
nude mice injected i.v. with 7 pLg 7 jzCi-' [1Ilbiotinylated
A5B7. Twenty-four hours later test groups received either
2 mg of fetuin or 2 mg of asialofetuin i.v., followed 15 min
later by galactosylated streptavidin injected i.p. at a 10-fold
molar excess of the antibody. Control mice received neither
fetuin nor asialofetuin. Fifteen minutes post gaiactosylated
streptavidin injection, all mice were sacrificed and blood and
tissbe radioactivity assessed.
The biodistribution data were caculated as percentage
injected dose per gram of tissue (% ID g-') and are mean
values from three or four mice at each time point.
Statistical analysis
The non-parametric Mann-Whitney U-test was used to com-
pare the difference between the groups. The results were
considered sin t when P<0.05.
Res
Biotinylated intact A5B7
Control experiments show no significant difference in the
biodistribution and tumour loclisation of A5B7 and
biotinylated A5B7 (data not shown).
We have previously shown that administraion of native
streptavidin will complex and clear biotinylated antibodies
from the blood via the liver and spleen (Marshall et al.,
1994), as illustrated in Figure 1, which shows the complexes
in the liver are soon degraded. The high liver radioactivity
seen 1 h after streptavidin administration was reduced to
below control levels by 24 h, in contrast to splenic uptake of
the complexes, which 24 h after streptavidin still remained
raised, resulting in a poor tumour to spleen ratio of only 3
compared with a ratio of 9.7 in the controls.
To assess whether galactosylated streptavidin (gal-strept-
avidin) would still complex and clear biotinylated A5B7 from
the blood and to establish the route of clarance, the effect of
a highly galwacosylated streptavidin (240 ag galactose per mg
of streptavidin), injected 24 h after the antibody was examin-
ed. Figure 2 shows a direct comparison between streptavidin
and gal-streptavidin cleaance of biotinylated A5B7. One
hour after native streptavidin, the radioactivity level in the
liver was raised from 3.2% ID g-' to 6.9% ID g-' (P<0.04)
and splenic radioactivity increased from 2.8% ID g- to
6.9% IDDg-I compared with the control, although the in-
crease was not statistically significant (P<0.3) because of a
large range in levels from 1.4%ID g-' to 11.2%ID g-' for
the cleared group. No high levels of splenic uptake were
observed 1 h after clearance with the galactose-modified
streptavidin (range 1.2-1.7% ID g-) and uptake of the gal-
streptavidin complexes was seen in the liver only (5.6%
ID g-'). Most of the biotinylated antibody had already been
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removed from the blood 1 h after administration of the
gal-streptavidin and the complexes degraded. The blood
levels 1 h after clearance indicate that gal-streptavidin com-
plexes were cleared from the blood faster than native strep-
tavidn complexes [2.7% ID g-' and 5.7% ID g-' (P<0.05)
respectively]. To further assess gal-streptavidin cearance of
biotinylated ASB7, earlier and later time points were
examined. A less galactosylated, but equally effective, strep-
tavidin (71 pg galactose per mg of streptavidin) was used in
these subsequent experiments.
Administration of gal-streptavidin 24h after ['251biotiny-
lated A5B7 produced a rapid decrease in the level of bio-
tinylated radiolabelled antibody in the circulation. Fifteen
minutes after injection of the gal-streptavidin clearing agent
(Figure 3a) a 7-fold reduction in the blood radioactivity lev
from 16.3 to 2.3% ID g-' resulted (P<0.04), accompanied
by a large rise in liver radioactivity from 5.8 to 26.7% IDg-'
(P<0.04), as the galactosylated streptavidin-biotinylated
antibody complexes were cleared. No significant difference in
tumour radioactivity was observed at this time point. Figure
3a also shows that 1 h after administration of gal-strep-
tavidin the radioactivity in the liver was 8.8% ID g-', show-
ing the complexes to have already cleared considerably from
this organ. Tumour radioactivity levels in the cleard group
showed no signint difference from control animals and
therefore clarance resulted in a much improved tumour to
blood ratio from 1.9 to 7.4 (P<0.04) at only 25h after
injection of the radiolabelled antibody.
Figure 3b shows that 24 h after injection of the gal-
sreptavidin the blood and all normal tissues had sigifintly
lowered (P<0.05) lewls of radioactivity. Although the level
of radioactivity in the tumour had also falen, this was to a
lesser extent than in the bkxld, and thus a much improved
(P<0.05) tumour to blood ratio of 13.2 was achieved com-
pared with only 2.8 without clearance, as shown in Figure 4.
The large error bar was due to a wide range of tumour to
blood ratios being observed after gal-streptavidin clearance,
the worst being 4.7, while the best tumour to blood ratio was
19.9.
Biotinylated A5B7F(ab')2
Control experiments show no significant difference in the
biodistribution and tumour localisation of A5B7 F(ab% and
biotinylated A5B7 (data not shown).
Figure 5 shows that the early clarance pattern of ['5I]-
biotinylated F(ab)2 after gal-streptavidin was similar to the
pattem seen with ['"1]biotinylated intact A5B7, with the
complexes being quickly taken up and rapidly cleared by the
liver (10% IDg-' and 5.3%IDg-' was seen in the liver
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Figure 5 Biodistribution of ['"I]biotinylated A5B7 F(ab')
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15 min and 1 h after gal-streptavidin, compared with 3.8%
ID g-' in the controls). Levels of biotinylated F(ab)} in the
blood were lowered considerably (P<0.03) to 4.4% ID g1'
and 3.4% ID g-' at 15 min and I h respectively in com-
panson with 11.7% ID g-' without clearance.
Biodistribution of ['"I]biotinylated F(ab')2 at later time
points is shown in Figure 6, using a different batch of F(ab')2
which gave superior tumour localisation to the previous
experiments. Fifteen hours after injection of gal-streptavidin
(24 h after biotinylated F(ab')2 injection) all normal tissues
had significantly lowered (P<0.03) levels of radioactivity,
with blood levels reduced from 5.6% ID g'l to 0.26% ID g- l
(21.5-fold reduction), as shown in Figure 6a. Tumour levels
of radioantibody were reduced non-significantly (P<0.2),
from 19.8% ID g-' to 11.9% ID g-', and therefore a 12.9-
fold increase (P<0.03) in the tumour to blood ratio resulted.
Figure 6b shows the biodistribution of the ["5IJbiotinylated
F(ab')2 24 h after gal-streptavidin administration. The
tumour was the only tissue with high levels of radioactivity
and, although this level was 2-fold lower (P<0.03) than in
controls without the gal-streptavidin clearing agent, the large
reduction in blood radioactivity levels means that the tumour
to blood ratio was greatly improved from 4.9 to 33.2
(P<0.03), as shown in Figure 7.
Effect offetuin and asialofetuin
Table I shows that asialofetuin, which is known to bind to
the asialoglycoprotein receptor (Ashwell and Morell, 1974),
inhibits the removal of gal-streptavidin-complexed ['"I]bio-
tinylated A5B7 from the blood. ['4Ilbiotinylated A5B7 is
shown to have cleared very rapidly via the liver 15 min after
injection of gal-streptavidin (control group), whereas 2 mg of
asialofetuin injected 15 min prior to administration of gal-
streptavidin inhibited blood clearance of the gal-strep-
tavidin-biotinylated A5B7 complexes [8.9% ID g-' remained
in the blood compared with only 1.9% ID g-" (P<0.03) in
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Figure 6 Biodistribution of ['"I]biotinylated
A5B7 F(ab') (a)
15 h and (b) 24 h post gal-streptavidin administration. The test
group ( ) was injected with gal-streptavidin 9 h after antibody
injection and compared with animals that did not receive gal-
streptavidin ( _ ). Results are expressed as percentage injected
dose per gram of tissue. Vertical bars indicate s.d.
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Fgre 7 Tissue to blood ratios ["IJbiotinylated A5B7 F(ab')
24 h post gal-streptavidin administration. The test group ()
was injected with gal-streptavidin 9 h after antibody injection and
compared with animals that did not receive gal-streptavidin
( _ ). Vertical bars indicate s.d.
Table I The effect of an asialoglycoprotein receptor inhibitor on the
percentage injected dose per gram (% IDg-') of ['"IJbiotinylated
ASB7 in the blood and liver after clearance with galactosylated
streptavidin
Blood % ID g Liver % IDg-'
Control 1.9 1.2 25.9 5.3
Asialofetuin 8.9 1.2 9.6 3.8
Fetuin 2.2 1.8 25.5 4.4
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the control group]. The very high liver uptake usually seen
with complex clarance was also reduced after asialofetuin
injection from 25.9 to 9.6% IDg-I (P<0.03). Fetuin (2 mg)
injected 15in prior to gal-streptavidin administration had
no effect on blood clarance or liver uptake of the com-
plexes.
Our previous work focused on how the degree of biotinyla-
tion affects the biodistribution of ['2I]biotinylated antibody
after administration of streptavidin to clear crculaing
radiolabelled antibody (Marshall et al., 1994). A larg
improvement in the tumour to blood ratio was achived
when nine or more bioins were conjugated to the antibody
(four biotn resdues resulted in no Improvement in the
tumour to blood ratio). The major problem noted was the
high and persistent levels of radioactivity in the spleen, and a
method to circumvent this splenic uptake was required.
Galactose conjugated to antibodies has been shown to
greatly increase their clarance from the circulation via the
liver (Mattes, 1987; Sharma et al., 1990). Mannose residues
have been successfuly conjugated onto streptavidin, without
mpairing biotin binding, to divert biotinylated oligodeoxy-
nucleotides to macrophages (Bonfils et al., 1992). In this
work we have conjugated galactose redues onto stetavidin
with a view to diting streptavidin complexes to the
asialoglycoprotein receptor of hepatocytes. Figure 2 shows
that the formation of streptavidin-biotinylated antibody
complexes was not impaired by conjugation of galactose to
streptavidin, giving good blood clarance, and we suass-
fully abolished the high spnic uptake of complexes pre-
viously seen with macrophage-dependent clearance using
native streptavidin (Marshall et al., 1994). The asialoglyco-
protein receptor binds galactosylated proteins rapdly and
strongly (K. is of the order of I09M-, the exact value being
dependent upon the ligand) and are very abundant (100 000-
500000 receptors per cell) (Schwartz, 1984), and therefore
this specific receptor-mediated endocytosis may account for
the more rapid removal of gal-streptavidin complexes from
the blood than uptake due to phagocytosis by macrophages
when native streptavidin was used. The minimal involvement
of non-target organs in clearing the radioantibodies and the
rapidity with which large tumour to blood ratios are
achieved with ['"l]biotinylated A5B7 makes this scheme ideal
for imaging. 131I-labelled antibodie are expected to show
similar results and Figure 4 illustrates the great improvement
in the potential therapeutic ratio which can be achieved 48 h
after antibody injection when gal-streptavidin clearance is
used. Iodine-labelled antibodies are known to be deiodinated
in vivo and clear rapidly from the liver. Antibodies labeled
with other therapeutic isotopes, such as radiometals, may not
be cleared in the same manner and therefore the effect of
gal-streptavidin ckarance on radiometal-labelled antibodies
also needs to be assessed.
This learance mechanism is of great interest because ofits
potential universal applcation to any anti-tumour antibody
(ysine residues are readily available for biotinylation), and it
was also ofinterest to establish the effect ofclarance on the
biodistnrbution and tumour locaistion of a F(ab% frag-
ment. The claring agent was given when tumour loalisation
of the antibody was at a peak, which is at an earlier time
point for F(ab% fragments than the peak seen with whole
IgG (Pedley et al., 1993), and therefore allowed earlier
administration of gal-streptavidin when using F(ab% frag-
ments. Thus the high and potentially damaging dose of
radioactivity received during the time prior to administration
of the cearing agent would be for a much shorter time if
F(ab% fragments were used.
The early clarance pattern of biotinylated F(ab% with
gal-streptavidin was similar to that seen with intact antibody
(transient high liver activity as the complexes are rapidly
ckared). Later time points revealed that 24 h after gal-
streptavidin clarance a smaller proportion of biotinylated
F(ab')2 was removed from the tumour than the proportion of
intact A5B7 removed. Figure 3b shows that localisation of
the biotinylated A5B7 in the tumour was reduced to only
37% of that seen without clarance, compared with a loss of
50% of the biotinylated F(ab% from the tumour 24 h after
gal-streptavidin (Figure 6b). This better retention of
biotinylated F(ab% in the tumour, together with lower blood
levels, resulted in a much improved tumour to blood ratio of
33:1 when compared with the ratio obtained 24 h after clear-
ance of biotinylated intact antibody (13.2:1), indicating that
F(ab% with clarance is superior to the cleared intact
antibody and therefore preferable for imaging studies. For
radioimmunotherapy a high dose of antibody at the tumour,
as weil as a large tumour to blood ratio, is required. A
comparison of the therapeutic effiacy of intact vs F(abJ)2
A5B7 has shown that the fragments, with higher tumour to
blood ratios, gave twice the radiation dose to the tumour
than was deivered by the intact antibody, for a similar
radioactivity dose to the blood and hence the bone marrow
(Pedley et al., 1993). A comparative dosimetry study of
biotinylated intact and F(ab% A5B7 with and without
clearance is' required in order to sekct the optimal
therapeutic modality.
The size of an anti-tumour antibody is known to affect its
biodistribution and clarance (Harwood et al., 1985; Yokota
et al., 1993) and the absolute amount of antibody which
locaises to the tumour has been shown in this work and by
others (Pedley et al., 1993; Vogel et al., 1993) to be less for a
fragment than an intact antibody. Pervez et at. (1988) and
Yokota et al. (1992) have carried out autoradiographic
studies to examine how penetration into the tumour differs
with the size of the antibody. These studies imply that at
early time points after antibody injection (comparable with
time of administration of gal-streptavidin in these experi-
ments), F(ab% will have penetrated deeper into the tumour
than whole IgG. The exact mechanism for the reduction in
antibody localition in the tumour after administration of a
clearing agent is unklnown, but could be circulatory clearance
combined with gal-streptavidin gaining access to the tumour,
where it can complex with tumour-bound biotinylated anti-
body, causing disociation from the tumour and clearance
from the body. Deeper penetration of F(ab% would mean
that antibody fragments are further from blood vessels than
whole IgG and therefore less likely to be available for com-
plexation with gal-streptavidin, resulting in a greater propor-
tion of the F(ab% remaining in the tumour after
clearance.
Evidence that the asialoglycoprotein receptor on hepato-
cytes is involved in the ckarance mechanism is shown in
Table I. Injection of asialofetuin 15 min prior to injection of
the gal-streptavidin was seen to inhibit blood clearance,
together with inhibiting liver uptake, of the gal-strept-
avidin-biotinylated A5B7 complexes. Injection of fetuin had
no such inhibiting effect, thus indicating that the asialo-
glycoprotein receptor of liver hepatocytes, known to bind
asialofetuin but not fetuin (Ashwell and Morell, 1974), is
involved in ckaring the complexes.
This study shows that the properties of not only the
antibody, but also the associated protems, direct the clear-
ance mechanism. Gal-streptavidin directed clearance via the
hepatocytes, whereas immune complexes of biotinylated anti-
bodies are normally cleared via the RES. Rifai et al. (1982)
also demonstrated that immune complexes could be directed
to either the parenchymal or non-parenchymal cells of the
liver depending on whether the antigen was rich in glactose
or mannose. Work by Krantz et al. (1976) showed a direct
relationship between the amount ofglactose conjugated to a
protein and its binding to liver membranes. In our work, a
decrease in the degree of galactosylation of the streptavidin
from 240 to 71 lzg ofgalactose per mg of streptavidin did not
effect the clearing pattern ofthe gal-streptavidin-biotinylated
antibody complexes, although it is possible that any further
reduction in the degree of galactosylation of streptavidin
could reduce its effectiveness in ckaring biotinylated com-
pounds, and further work to establish the minimum degree ofAntibody clearance using galactosylated streptavidin
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galactose conjugation required for effective clearance has yet
to be carried out.
Galactosylation could be beneficial for other avidin-biotin
tumour targeting schemes. Ogihara-Umeda et al. (1993, 1994)
used avidin to clear biotin-bearing liposomes. As with strep-
tavidin clearance of biotinylated antibodies, high splenic
uptake was seen after clearance and therefore galactosylated
streptavidin should circumvent this problem. Streptavidin has
also been used in two-step pretargeting in which radio-
labelled streptavidin is injected after preadministration of
cold biotinylated anti-tumour antibody. Saga et al. (1994)
reported liver and splenic radioactivity levels to be higher
after pretargeting than when radiolabelled streptavidin alone
was injected as a result of the formation of strep-
tavidin-biotinylated antibody complexes and their uptake by
the RES. Galactosylation of the streptavidin would limit this
uptake to the liver alone. Gal-streptavidin may also be of use
in the three-step protocol of Paganelli et al. (1990b, 1991), in
which avidin is used to clear cold biotinylated antibody
before administration of the isotope.
We have previously shown that the administration of
streptavidin will rapidly clear biotinylated radioantibodies
from the circulation via the liver and spleen, producing much
improved tumour to blood ratios compared with antibody
alone. The liver rapidly dehalogenates the iodinated com-
plexes and the free iodine is excreted, whereas complexes
cleared via the spleen tend to be metabolised at a much
slower rate. By using a galactosylated form of streptavidin,
we have enhanced the antibody clearance by removing accu-
mulation of radioactive antibody complexes which persist in
the spleen without increasing liver accumulation (Figure 2
shows that liver radioactivity is approximately the same 1 h
after both streptavidin and gal-streptavidin clearance). Galac-
tosylation of the clearing agent, and thus exploitation of the
asialoglycoprotein receptors on hepatocytes of the liver,
reduces damage which may be caused by prolonged exposure
of radioactivity to normal tissues. Biotinylation, via lysine
residues, is a mild procedure (only limited reduction in the
immunoreactivity of A5B7 was found) and should be applic-
able to any anti-tumour antibody. This universal clearance
scheme, with increased tumour to blood ratios and minimal
involvement of normal tissues, should greatly improve anti-
body-targeted imaging and therapy of cancer. It is of use not
only for radioimmunotherapy but also for targeted therapy
of toxins/drugs including antibody-directed enzyme pro-drug
therapy (ADEPT) (Bagshawe, 1987), when very low levels of
the antibody enzyme conjugate in the blood and normal
tissues are essential before the prodrug can be administered.
There is also potential for controlling clearance of any phar-
maceutical drug which can be biotinylated. This would be
useful for controlling the duration of exposure to a drug or
for clearing drugs via the liver when their normal organ of
clearance (e.g. the kidney) is impaired.
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